Sweden's Hansa Biopharma Q4 revenue surges on strong IDEFIRIX sales

Hansa Biopharma AB

11/02/2026 06:12

Overview

Sweden biopharma's Q4 revenue rose 135% yr/yr

Company submitted BLA for imlifidase to FDA for kidney transplantation

Company raised 671.5 MSEK in directed share issue

Outlook

Hansa seeks Priority Review for imlifidase BLA with FDA, aims for FDA approval and U.S. launch of imlifidase in 2026

Company plans FDA interactions for HNSA-5487 in Guillain-Barré syndrome

Result Drivers

IDEFIRIX SALES GROWTH - Q4 IDEFIRIX product sales rose 139% to SEK 61.1 mln driven by adoption in European markets

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
SEK 76 mln
Q4 Adjusted EPS
-SEK 1.62
Q4 Net Income
-SEK 165 mln
Q4 Cash & Investments
SEK 701.10 mln
Q4 EBIT
-SEK 124.90 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Hansa Biopharma AB is SEK84.00, about 127.1% above its February 10 closing price of SEK36.98

Press Release: ID:nWkr8PsNjh

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)